Compare ORGO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORGO | IMUX |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 155.8M |
| IPO Year | 2016 | 2013 |
| Metric | ORGO | IMUX |
|---|---|---|
| Price | $1.04 | $7.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $2.00 | ★ $43.09 |
| AVG Volume (30 Days) | ★ 750.4K | 392.8K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1600.00 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $564,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $0.93 | $0.51 |
| 52 Week High | $7.08 | $17.43 |
| Indicator | ORGO | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 26.19 | 33.34 |
| Support Level | N/A | $6.35 |
| Resistance Level | $2.57 | $8.60 |
| Average True Range (ATR) | 0.08 | 0.65 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 22.22 | 36.89 |
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.